CEO and managing director Dr Paul McKenzie said, “CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in our core Ig franchise. We continue to advance key initiatives to improve gross margin, which is tracking according to our plans."
Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus
February 11, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Australian researchers solve decades-long mystery on Parkinson’s disease
March 14, 2025 - - Australian Biotech -
Kosi climbers about to embark on day one of 2025 challenge
March 14, 2025 - - Latest News -
Astellas cancer therapy approved for new indication in earlier prostate cancer
March 14, 2025 - - Latest News -
World-first study identifies 'Goldilocks' number of genes to include in pre-pregnancy screening
March 13, 2025 - - Latest News -
Medicines funded by Pharmac tops 50 since last year's budget boost
March 13, 2025 - - Latest News -
Australia is not alone in using rebate payments, but there are some differences
March 13, 2025 - - Latest News -
Australian company confirms the location of key clinical trial
March 13, 2025 - - Australian Biotech